Chester County News and Community Website
BERWYN, PA — Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) recently released its financial results for the first quarter of 2024, revealing increased losses as the company advances its drug development programs.
Virpax Pharmaceuticals Reports Increased Losses Amid Promising Developments Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) has unveiled hopeful results from its Maximum Tolerated Dose (MTD) study of Probudur™, a long-acting pain management drug, in Sprague-Dawley rats. Probudur, …
Virpax Pharmaceuticals’ Probudur Shows Promising Results in Pain Management Study Read More BERWYN, PA — Recent developments have been flourishing for Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX). The Pennsylvania-based pharmaceutical innovator recently unveiled its financial records for 2023 and shared a series of …
Virpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management Solutions Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced initial positive results from a pilot study of its pain management drug candidate, Probudur™. The study was conducted under an …
Virpax Pharmaceuticals Reports Promising Results in Probudur Pilot Study Read More BERWYN, PA — In a recent Special Meeting of Shareholders, Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) revealed that its stockholders had given the green light for a reverse stock split. The …
Virpax Pharmaceuticals Shareholders Approve Reverse Stock Split Amid Nasdaq Compliance Efforts Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX), a company specializing in non-opioid pain management therapies, has announced significant changes to its leadership team amidst ongoing litigation. The company recently …
Virpax Pharmaceuticals Announces Leadership Changes; Gerald Bruce Appointed CEO, Dr. Eric Floyd Named Chairman Read More BERWYN, PA — Virpax® Pharmaceuticals, Inc. (NASDAQ: VRPX) has recently revealed its financial results for the third quarter ending September 30, 2023, alongside a series of significant developments.
Virpax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Announces New Developments Read More BERYWN, PA — In a significant move that promises to reshape the future of pain management, Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) recently announced its intent to submit an Investigational New …
Virpax Pharmaceuticals’ Envelta Set for Human Trials Following FDA Review: A Potential Game-Changer in Pain Management Read More